The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro
Elke Tatjana Aristizabal Prada(Ludwig-Maximilians-Universität München), Christoph J. Auernhammer(LMU Klinikum)
Cited by 23